Aan dit artikel is enkele uren gewerkt. Opzoeken, vertalen, eventuele referenties of ander vergeljkbare studies zoeken, plaatsen enz. Wellicht wilt u ons daarin ondersteunen door een donatie te doen, al of niet anoniem en elk bedrag, hoe klein ook is welkom. Als u hier klikt kunt u online een donatie doen en helpt ons om kanker-actueel online te houden.

19 september 2016: lees ook dit artikel:

https://kanker-actueel.nl/NL/tcm-traditionele-chinese-medicijnen-naast-westerse-medicijnen-voor-gevorderde-niet-kleincellige-longkanker-geeft-langere-levensduur-betere-kwaliteit-van-leven-in-vergelijking-met-alleen-westerse-medicijnen.html

3 december 2011: Bron: J Exp Clin Cancer Res. 2010; 29(1): 137. Published online 2010 October 22. doi: 10.1186/1756-9966-29-137

Wanneer longkankerpatiënten met niet-klein-cellige longkanker naast op platinum gebaseerde chemo ook injecties krijgen met een mix van Chinese kruiden - Shenqi Fuzheng, dan is het behandelingsresultaat beduidend beter. De patiënten leven langer en met betere kwaliteit van leven. Dit toont een meta analyse aan van 29 gerandomiseerde studies. In alle studies is een vergelijk gemaakt tussen alleen chemo of chemo plus Shenqui fuzheng injecties. Dat TCM - traditionele Chinese kruiden goed werken bij longkanker, maar ook bij andere vormen van kanker is al veel vaker aangetoond. Zie o.a. in linkerkolom. Bij de natuurapotheek in Pijnakker zijn de meeste werkzame Chinese kruiden te verkrijgen.

RESULTATEN: 29 studies werden opgenomen in dit onderzoek op basis van onze selectiecriteria. daaronder waren tien studies van hoge kwaliteit en de rest waren van lage kwaliteit, volgens de Jadad schaal. De meta-analyse toonde aan dat er een statistisch significant hogere behandelings reactie was op de tumoren zelf (RR, 1,19, 95% BI, 1,07 tot 1,32, p = 0,001) en de performance status - kwaliteit van leven ((RR, 1,57, 95% BI, 1,45 tot 1,70; P <0.00001 ), en minder ernstige toxiciteit - bijwerkingen voor de combinatiegroep van chemo en de injecties - WBC (RR, 0,37, 95% BI, 0,29 tot 0,47; p <0,00001), PLT (RR, 0,33, 95% BI, 0,21 tot 0,52; p <0,00001), HB (RR, 0,44 95% BI, 0,30 tot 0,66, P <0,0001) en misselijkheid en braken (RR, 0,32, 95% BI, 0,22 tot 0,47; p <0,00001), wanneer de SFI plus op platina gebaseerde chemotherapie behandelde groep werd vergeleken met de platina -gebaseerde chemotherapie controlegroep. Een analyse welke beperkt werd tot studies met hoge kwaliteit tonde aan dat het resultaat vergelijkbaar was als de studies met een lage kwaliteit niet werden uitgesloten.

Hieronder het abstract van deze meta analyse. Het volledige studierapport van individuele studies is gratis in te zien als u op deze link klikt. Onderaan dit artikel staat een referentielijst van 52 studies die op een of ander manier gerelateerd zijn aan deze studie

Shenqi fuzheng, an injection concocted from chinese medicinal herbs, combined with platinum-based chemotherapy for advanced non-small cell lung cancer: a systematic review

J Exp Clin Cancer Res. 2010 Oct 22;29:137.

Shenqi fuzheng, an injection concocted from Chinese medicinal herbs, combined with platinum-based chemotherapy for advanced non-small cell lung cancer: a systematic review.

Dong J, Su SY, Wang MY, Zhan Z.

Source

Institute of Basic Medical Science, Nanjing University of Traditional Chinese Medicine, Nanjing, P.R. China.

Abstract

BACKGROUND:

Platinum-based chemotherapy has been a standard therapy for advanced non-small cell lung cancer (NSCLC), but it has high toxicity. In China, Shenqi Fuzheng, a newly developed injection concocted from Chinese medicinal herbs has been reported that may increase efficacy and reduce toxicity when combined with platinum-based chemotherapy, but little is known about it outside of China. The aim of this study was to systematically review the existing clinical evidence on Shenqi Fuzheng Injection(SFI) combined with platinum-based chemotherapy for advanced NSCLC.

METHODS:

Pubmed, Cochrane Library, EMBASE, CNKI, and CBM search were organized for all documents published, in English and Chinese, until April 2010. The randomized controlled clinical trials were selected based on specific criteria, in which a SFI plus platinum-based chemotherapy treatment group was compared with a platinum-based chemotherapy control group for patients with advanced NSCLC. The quality of studies was assessed by modified Jadad's scale, and Revman 4.2 software was used for data syntheses and analyses.

RESULTS:

Twenty nine studies were included in this review based on our selection criteria. Of them, ten studies were of high quality and the rest were of low quality, according to the modified Jadad scale. The meta-analysis showed there was a statistically significant higher tumor response (RR, 1.19; 95% CI, 1.07 to 1.32; P = 0.001) and performance status ((RR, 1.57; 95% CI, 1.45 to 1.70; P < 0.00001); but lower severe toxicity for WBC (RR, 0.37; 95% CI, 0.29 to 0.47; P < 0.00001), PLT (RR, 0.33; 95% CI, 0.21 to 0.52; P < 0.00001), HB (RR, 0.44; 95% CI, 0.30 to 0.66; P < 0.0001) and nausea and vomiting (RR, 0.32; 95% CI, 0.22 to 0.47; P < 0.00001), when the SFI plus platinum-based chemotherapy treatment group was compared with the platinum-based chemotherapy control group. Sensitivity analysis was restricted to studies with the high quality, and the result was similar when the studies with low quality were excluded. Asymmetry was observed in a funnel plot analysis, and Egger's test also indicated an evidence of publication bias (P = 0.016).

CONCLUSIONS:

SFI intervention appears to be useful to increase efficacy and reduce toxicity when combined with platinum-based chemotherapy for advanced NSCLC, although this result needs to be further verified by more high-quality trials.

PMID:: 20969765; [PubMed - indexed for MEDLINE]
PMCID: PMC2972256

References

Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–594. doi: 10.4065/83.5.584. [PMC free article] [PubMed] [Cross Ref]
Suresh R, Chandra P. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. The Oncologist. 2008;3(suppl 1):5–12.
Barlesi F, Pujol JL, Daures J-P. Should chemotherapy (Cx) for advanced non-small cell lung cancer (NSCLC) be platinum-based? a literature-based meta-analysis of randomized trials. J Clin Oncol. 2005;23(16s):673s.
D'Addario G, Pintilie M, Leighl NB, Fied R, Gerny T, Shepherd FA. Platinum-based versus non platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol. 2005;23(13):2926–2936. doi: 10.1200/JCO.2005.03.045. [PubMed] [Cross Ref]
McCulloch M, See C, Shu XJ, Broffman M, Kramer A, Fan WY, Gao J, Lieb W, Shieh K, Colford JM Jr. Astragalus-based chinese herbs and platinum-based chemotherapy for advanced non small cell lung cancer: meta-Analysis of randomized trials. J Clin Oncol. 2006;224(3):419–430. doi: 10.1200/JCO.2005.03.6392. [Cross Ref]
Wu BC, Xu L, Chen M. Meta-analysis of Ai Di injection combined with NP chemotherapy in the treatment of late stage non-small cell lung cancer. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine. 2009;19(7):446–447.
Yang LR, Xu XY. Clinical application and curative effect evaluation of Shenqi fuzheng injection. Heilongjiang Journal of Traditional Chinese Medicine. 2004;4:46–48.
Lu Y, Lu YX. Clinical application and pharmacology function of Shenqi fuzheng injection. Li Shi Zhen Medicine and material medica research. 2006;17(10):2083–2085.
Pan L. Practical road of "the numeral turn Chinese herbal medicine" for Shenqi fuzheng injection. Journal of China Prescription Drug. 2009;1(82):37–39.
Zhong ZH. Dictate history: A national new medicine that come from experiential prescription. Journal of China Prescription Drug. 2009;1(82):33–36.
Higgins J, Green S. , (eds) Cochrane handbook for systematic reviews of interventions 4.2.6. In the Cochrane library. 4. Vol. 301. Wiley: Chichester; 2006. (updated September 2006)
WHO. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, World Health Organization; 1979.
Yates JW, Chalmer B, McKegney FP. Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer. 1980;45:2220–2224. doi: 10.1002/1097-0142(19800415)45:8<2220::AID-CNCR2820450835>3.0.CO;2-Q. [PubMed] [Cross Ref]
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188. doi: 10.1016/0197-2456(86)90046-2. [PubMed] [Cross Ref]
Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Methods for Meta-Analysis in Medical Research. Chichester, United Kingdom, John Wiley & Sons; 2000.
Delbaldo C, Michiels S, Syz N. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: A meta-analysis. JAMA. 2004;292:470–484. doi: 10.1001/jama.292.4.470. [PubMed] [Cross Ref]
Oremus M, Wolfson C, Perrault A, Demers L, Momoli F, Moride Y. Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer's disease drug trials. Dement Geriatr Cogn Disord. 2001;12:232–236. doi: 10.1159/000051263. [PubMed] [Cross Ref]
Breierova L, Choudhari M. An introduction to sensitivity analysis. MIT Pr; 1996. pp. 41–107.
Egger M, Davey SG, Altman DG. Systematic reviews in health care: Meta-analysis in context. London: BMJ books; 2001.
Hao XL, Lv XJ. The influence of Shenqi fuzheng injection combined with chemotherapy on the survival quality of late-stage non-small cell lung cancer. Chinese Journal of Practical oncology. 2008;22(5):458–459.
Wang K, Tan JX, Nong Y. Clinical observation of Shenqi fuzheng injection combined with NP chemotherapy in the treatment of late stage non-small cell lung cancer. Modern Journal of Integrated Traditional Chinese and Western Medicine. 2007;16(26):3797–3798.
Kang GY, Li B. Shenqi fuzheng injection combined with chemotherapy for the late stage non-small cell lung cancer 36 cases. Chinese Journal of Integrative Medicine. 2006;26(6):565–566.
Gong ZM, Wang Y, Yu CY, Chen HY. Clinical observation of Shenqi fuzheng injection combined with NP chemotherapy for the elder late-stage non-small cell lung cancer. Information on Traditional Chinese Medicine. 2008;15(9):64–65.
Wang XY, Hang ZQ, Li H, Cai CB. Clinical observation and nursing of Shenqi fuzheng injection combined with NP chemotherapy for the elder late-stage non-small cell lung cancer. Journal of Chinese Lung Cancer. 2007;10(3):234–236.
Wang YZ, Yang ZX, Liao SH, Shen X. Clinical observation of Shenqi fuzheng injection combined with vinorelbine plus carboplatinum for the late stage non-small cell lung cancer. Journal of Chinese clinical intern Medicine. 2007;24(3):206–207.
Li TW, Xiang L, Tong FY, Zhang CH. Clinical observation of Shenqi fuzheng injection combined with chemotherapy for the late stage lung cancer. Journal of Progress in Modern Biomedicine. 2009;9(10):1917–1919.
Li Y, Chen SX, Huang RW. Clinical observation of Shenqi fuzheng injection combined with NP chemotherapy for the late stage non-small cell lung cancer. Journal of Chinese Modern Medicine. 2007;9(3):40–41.
Lv J. Clinical observation of Shenqi fuzheng injection combined with chemotherapy for the late stage non-small cell lung cancer. China Medical Herald. 2008;5(36):73–74.
Zhao ZY, Wu DL, Chen M, Jiang H, Yan GJ. The short-term curative effect of Shenqi fuzheng injection combined with NP chemotherapy for the elder late stage non-small cell lung cancer. Journal of Chinese modern oncology. 2007;15(1):42–43.
Geng L. Shenqi fuzheng injection combined with chemotherapy for the non-small cell lung cancer. Journal of Medical Forum. 2004;25(17):29–30.
Yu QZ. Shenqi fuzheng injection combined with chemotherapy for the middle and late stage non-small cell lung cancer. Chinese Journal of Integrative Medicine. 2007;27(5):473–474.
Liu CL, Chen WP, Cui SZ, Den GY, Liu LP, Tan LH, Su XC, Yan BC, Kong JX. Clinical observation of Shenqi fuzheng injection combined with chemotherapy for the elder non-small cell lung cancer. Chinese Journal of Integrative Medicine. 2004;24(10):901–903.
Liu FH, Liao GQ, Wang HM. The curative effect observation of Shenqi fuzheng injection combined with chemotherapy for the late stage lung cancer. Journal of Third Military Medical University. 2007;29(3):259–260.
Pan YK, Huang M, Qu M. Clinical observation of Shenqi fuzheng injection assisted with chemotherapy for the non-small cell lung cancer. Journal of Chinese Clinical Medical. 2008;3(4):43–45.
Zhen JH, Chen YF. Shenqi fuzheng injection combined with NP chemotherapy in treating elder late stage non-small cell lung cancer patients 42 cases. JiangXi Journal of Traditional Chinese Medicine. 2009;40(6):58–59.
Miao SR, Yang WH, Geng CH. Clinical observation of Shenqi fuzheng injection combined with NP chemotherapy in treating elder late stage non-small cell lung cancer. Chinese Journal of Practical Medicine. 2010;5(11):16–17.
Li YQ, Zhou X, Zhang T, Chen HJ. The clinical study on reducing toxicity effect of Shenqi fuzheng injection combined with NP chemotherapy for non-small cell lung cancer. Chinese Journal of New Drugs. 2010;19(2):23–126.
Geng D, Cui JC, Ma L. The curative effect observation of Shenqi fuzheng injection combined with NP chemotherapy for the late stage non-small cell lung cancer. Chinese Journal of Practical Medicine. 2007;2(5):57–59.
Zou Y, Bo YJ, Ruan PG. Clinical observation of Shenqi fuzheng injection combined with paclitaxel plus carboplatinum chemotherapy in treating patients with late stage non-small cell lung cancer. Chinese Journal of Practical oncology. 2005;20(3):260–262.
Luo SZ, Long JH, Yu XY. Clinical observation of Shenqi fuzheng injection combined with paclitaxel plus cisplatinum chemotherapy for late stage non-small cell lung. Journal of Chinese cancer research and clinic. 2006;18(3):181–183.
Luo SW, Huang YP, Shan HL, Yang YW, Mo C, Wu XE. Clinical observation of middle and late stage non-small cell lung cancer treated with Shenqi fuzheng injection combined with paclitaxel plus carboplatinum. Chinese Journal of Clinical Oncology. 2007;12(5):381–382.
Zhang FL. Clinical observation of middle and late stage non-small cell lung cancer treated with Shenqi fuzheng injection combined with paclitaxel plus carboplatinum. Journal of Chinese Modern Oncology. 2008;16(7):1165–1166.
Zhao YX, Wang CY, Li J, Wang F. The curative effect observation of Shenqi fuzheng injection combined with paclitaxel plus carboplatinum for non-small cell lung cancer. Journal of Chinese misdiagnose. 2009;19(21):5129–5130.
Yu F, Li K. Clinical observation of Shenqi fuzheng injection assisted with chemotherapy for non-small cell lung cancer. Chinese Journal of Integrative Medicine. 2007;21(2):166–167.
He WJ, Zhao JQ. Clinical observation of Shenqi fuzheng injection combined with gemcitabine plus cisplatinum for late stage Non-small Cell Lung Cancer. Journal of Chinese progress in oncology. 2008;6(4):432–434.
Liang K, Li SY. The curative effect observation of Shenqi fuzheng injection combined with chemotherapy for non-small cell lung cancer. Journal of Chinese Tropical Medicine. 2010;10(4):498–499.
Chen J, Jia YJ, Sun YY, Zhang YC. The clinical observation of Shenqi fuzheng injection combined with chemotherapy for non-small cell lung cancer. Chinese Medicine Emergency. 2007;16(8):911–912.
Wu L, Jiang B, Yang J, Li H. Shenqi fuzheng injection combined with chemotherapy in treating elder late stage non-small cell lung cancer patients 30 cases. Chinese Journal of Integrative Medicine. 2004;24(6):567–568.
Michael Borenstein L, Hedges V, Higgins JPT, HRIntroduction to Meta-Analysis. Rothstein© John Wiley & Sons, Ltd; 2009.
Ma XQ, Shi Q, Duan JA, Dong TT, Tsim KW. Chemical analysis of Radix Astragali (Huangqi) in China: a comparison with its adulterants and seasonal variations. J Agric Food Chem. 2002;50:4861–4866. doi: 10.1021/jf0202279. [PubMed] [Cross Ref]
Shao BM, Xu W, Dai H, Tu P, Li Z, Gao XM. A study on the immune receptors for polysaccharides from the roots of astragalus membranaceus, a chinese medicinal herb. Biochem Biophys Res Commun. 2004;320:1103–1111. doi: 10.1016/j.bbrc.2004.06.065. [PubMed] [Cross Ref]
Jiao HJ. The pharmacology efficacy and clinical application about dangshen. Chinese Journal of Clinical Medicine. 2005;25(4):89–92.